JMP Securities Cuts Integra LifeSciences (NASDAQ:IART) Price Target to $25.00

Integra LifeSciences (NASDAQ:IART) had its price target decreased by JMP Securities from $35.00 to $25.00 in a research report sent to investors on Friday,Benzinga reports. JMP Securities currently has a market outperform rating on the life sciences company’s stock.

Several other equities research analysts also recently issued reports on IART. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Wells Fargo & Company reduced their price target on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Truist Financial cut their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 6th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $18.63.

Integra LifeSciences Price Performance

Shares of IART stock opened at $12.25 on Friday. The firm’s 50 day moving average is $18.93 and its 200-day moving average is $21.91. The firm has a market capitalization of $951.97 million, a price-to-earnings ratio of -136.10, a PEG ratio of 0.73 and a beta of 1.27. Integra LifeSciences has a 1 year low of $11.60 and a 1 year high of $32.66. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the prior year, the company earned $0.55 earnings per share. The company’s quarterly revenue was up 3.7% on a year-over-year basis. Sell-side analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently bought and sold shares of the business. Nordea Investment Management AB increased its stake in Integra LifeSciences by 4.1% in the fourth quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after acquiring an additional 5,032 shares during the last quarter. Romano Brothers AND Company acquired a new position in Integra LifeSciences during the 4th quarter worth about $204,000. Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in shares of Integra LifeSciences in the 4th quarter worth approximately $204,000. Nisa Investment Advisors LLC raised its position in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after acquiring an additional 2,800 shares in the last quarter. Finally, Choreo LLC boosted its stake in Integra LifeSciences by 29.9% during the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock worth $500,000 after acquiring an additional 5,123 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.